Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.
H UekiN HinataK KitagawaT HaraT TerakawaJ FurukawaK HaradaY NakanoM KomatsuM FujisawaToshiro ShirakawaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
PD-L1 expression in tumor cells was associated with poor prognosis (OS and PFS) and low DCR. Interestingly, the strong expression of Nectin-4 was correlated with high DCR. PD-L1 and Nectin-4 expression in tumor cells could be prognostic biomarkers useful for pembrolizumab in patients with advanced UC.